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Comparison of helmet and facial mask during noninvasive
ventilation in patients with acute exacerbation of chronic obstructive
pulmonary disease: a randomized controlled study
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Background/aim: Noninvasive mechanical ventilation (NIMV) is an approach to prevent complications in acute respiratory failure. In
this study we aimed to compare the efficacy of a full face mask and a helmet in chronic obstructive pulmonary disease (COPD).
Materials and methods: Fifty patients were divided randomly into 2 groups as full face mask (Group F) and helmet (Group H).
Demographic data, forced expiratory volume at 1 s (FEV1), additional disease, hemodynamic parameters, respiratory rate, APACHE II
score, peripheral O2 saturation (SpO2), arterial blood gases (ABG), patient tolerance scale (PTS) score, and fraction of inspired oxygen
(FiO2) were recorded. Parameters were recorded as follows: 20 min before the NIMV; every 30 min of NIMV until 120 min; 30 min, 24
h, and 48 h after NIMV; and prior to intensive care unit discharge.
Results: The SpO2, PTS, ABG, complication rate, and APACHE II scores were not different between the groups (P > 0.05). The decrease
in PaCO2 was statistically significant at 60 min in Group F (P < 0.05), and there was no statistical difference in Group H (P < 0.05)
according to initial PaCO2 values.
Conclusion: Both masks are efficient in improving the patients’ outcome in COPD, but the decrease in PaCO2 in the helmet group was
slower than in the full face mask group.
Key words: Chronic obstructive pulmonary disease, noninvasive mechanical ventilation, helmet, full face mask

1. Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable disease characterized by partially reversible
airway obstruction (1). Acute exacerbations are the most
important cause of morbidity and mortality in COPD.
Recurrent episodes (2 to 3 attacks per year) are frequently
observed in the course of COPD. Hypoxic and hypercapnic
respiratory failure may develop due to COPD exacerbation
(2). Invasive mechanical ventilation (IMV) is an option for
management of COPD exacerbation, but its complication
rate is quite high. The main complications are ventilatorassociated pneumonia and tracheal damage and stenosis
because of the endotracheal tube (3). Noninvasive
mechanical ventilation (NIMV) is another option for the
treatment of COPD exacerbation. NIMV via nasal-facial
mask or helmet is a choice of therapy for the treatment of
acute COPD exacerbation (4). The advantages of NIMV are
maintenance of airway protection mechanisms, the ability
to swallow and speak, and a reduction in the sedation
* Correspondence: mdalagoz@gmail.com
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requirement. Air leakage, improper mask position, and
patient distress are the most important reasons for NIMV
failure (5–7). Recently, the helmet has been introduced as
an alternative interface for NIMV alongside full face and
oro-nasal masks (8,9).
In this study we aimed to compare the efficacy and
complication rates of a full face mask and a helmet in cases
of COPD acute exacerbation.
2. Materials and method
After approval from the institutional review board and all
patients, 50 COPD patients admitted to the respiratory
intensive care unit (ICU) due to acute exacerbation of
COPD between December 2011 and May 2012 were
randomly included in this study. All patients were
previously diagnosed with COPD according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria (10). In cases of COPD exacerbation, NIMV was
routinely applied to the patients based on general criteria
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[respiratory rate (RR) of >25/min, PaCO2 of >45 mmHg,
and pH of <7.35]. COPD exacerbation was defined by the
presence of the following criteria: increase in dyspnea, and
increase in quantity and purulence of sputum (10). The
COPD exacerbation treatments given to all patients were
subcutaneous heparin, systemic steroids, bronchodilators,
and, if necessary, antibiotics. Electrolyte abnormalities
were also corrected.
Patients who had an IMV indication, unstable
hemodynamic situation (systolic arterial pressure (SAP)
of <90 mmHg and mean arterial pressure (MAP) of <50
mmHg), cooperation problems, neurologic disorders,
facial trauma, facial surgery or deformity, pleural effusion,
or malignant diseases were excluded from the study.
Age, sex, height, weight, body mass index (BMI), FEV1,
presence of additional disease, heart rate (HR), MAP, SAP,
diastolic arterial pressure (DAP), RR, Acute Physiology
Assessment and Chronic Health Evaluation (APACHE) II
score, peripheral O2 saturation (SpO2), arterial blood gases
(ABG) measurements, and fraction of inspired oxygen
(FiO2) were recorded. We also recorded complications,
intubation requirements, duration of ICU and hospital
stay, and duration of treatment.
Patients were observed closely during the study
period. Nasal oxygen was administered to the patients
to keep their SpO2 between 85% and 92% prior to study.
NIMV was started with patients in a sitting position, and
bilevel positive airway pressure was performed using a
mechanical ventilator (Servo Maquet S; Getinge Group,
USA). Initial NIMV modes were setup as FiO2 0.4, positive
end expiratory pressure (PEEP) 5–7 cmH2O, pressure
support (PS) 10 cmH2O, and trigger –2 cmH2O.
Patients were randomly divided into 2 groups as
full face mask (Group F, n = 25) and helmet (Group H,
n = 25) in the ICU. The NIMV was started using full a
face mask (Respironic-S Facial Mask; Teleflex Medical,
Ireland) in Group F and a helmet (CaStar; Starmed, Italy)
in Group H. PS was gradually increased by 2 cmH2O steps
during the first hour of ventilation to observe adequate
patient respiratory effort. The FiO2 rate was also increased
gradually up to 50% by 5% steps to obtain at least 92%
SpO2. Our aim was to provide 6–8 mL/kg tidal volume
during the NIMV procedure. During NIMV, ABG was
checked every 30 min, and FiO2 was reset according to
ABG results. The NIMV settings were recorded after the
initial period and NIMV was kept continuous for 2 h with
these settings.
Parameters were recorded at 20 min before the NIMV
(T0) and at initiation of NIMV (T1), 30 min of NIMV
(T2), 60 min of NIMV (T3), 90 min of NIMV (T4), 120
min of NIMV (T5), 30 min after NIMV (T6), 24 h after
NIMV (T7), 48 h after NIMV (T8). Values during ICU
discharge were also recorded (T9). The ABG was recorded

at times T2, T3, T4, T5, T6, T7, T8, and T9 in all patients.
The RR, hemodynamic values (SAP, DAP, MAP, and HR),
and PaO2/FiO2 values were recorded. Compliance of
patients to the mask and helmet was evaluated by using
the patient tolerance scale (PTS) at the first and second
hours of NIMV, using a blackboard. PTS was evaluated as
follows.
1. Bad: Patients try to remove mask.
2. Moderate: Mask ventilation is successful with
suggestions.
3. Good: Mask is somewhat disturbing to patients, but
they want to use it.
4. Excellent: Complete tolerance.
Face laceration and erythema in Group F and axillary
erythema and laceration in Group H were accepted as
mask-related complications. Duration of ICU, duration
of NIMV, IMV requirements, and mortality rate were
recorded. Study-related axillary and face pressure wounds
and erythema were recorded at the end of the study.
2.1. Statistical analysis
It was found that each group’s sample size should be at
least 19 in order to determine a 40% difference between
the groups’ success rates at 0.05 type I error rate and 80%
power. Statistical analysis was performed using SPSS
for Windows 15.0 (SPSS Inc., Chicago, IL, USA). For
continuous variables, the normality of the distribution
was checked. Descriptive statistics were given as mean
± standard deviation if the distribution of variables was
normal. Median (25th–75th percentile) was used for the
variables that were not normally distributed. Differences
between the 2 groups were compared with independent
sample t-test and Mann–Whitney U test for normally
and nonnormally distributed variables, respectively.
To evaluate the parametric data in the groups, twoway analysis of variances for repeated measures was
used. The Friedman test was performed to evaluate the
nonparametric data in the groups. When differences
existed, pairwise comparisons were done by Bonferroni
test. Categorical variables were compared by chi-square
test. P-values of less than 0.05 were accepted as significant.
3. Results
Forty-eight patients (Group F, n = 23; Group H, n = 25)
completed this study. Two patients were excluded from the
study due to resistant respiratory acidosis during NIMV
procedure in Group F. The mean age was significantly
higher in Group H (P < 0.05). There was no difference
between groups in terms of demographic values (P >
0.05) (Table 1). The MAP, DAP, SAP, and HR values were
comparable between the groups (P > 0.05).
There was no significant difference between the groups
in terms of initial respiratory, ABG, and NIMV parameters
(P > 0.05) (Table 2).
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Table 1. Demographic characteristics of the patients.
Group F (n = 23)

Group H (n = 25)

P-value

(mean ± SD)

(mean ± SD)

Age (years)

64.3 ± 10.1

69.5 ± 7.41

0.044*

APACHE II

16.87 ± 4.78

16.48 ± 3.89

0.758

Sex (F/M)

8/15

6/19

0.610

BMI

28.06 ± 6.58

25.02 ± 4.48

0.060

Comorbidity (%)

14 / 23 (61)

16/25 (24)

1.000

*P < 0.05: Compared between the groups. Values presented as mean ± standard deviation
(SD) or patient number and percentage. F: Female, M: male, H: helmet, F: full face mask,
BMI: body mass index, APACHE II: Acute Physiology Assessment and Chronic Health
Evaluation II.

Table 2. Initial noninvasive mechanical ventilation and respiratory parameters.
Group F (n = 23)
(mean ± SD)

Group H (n = 25)
(mean ± SD)

P-value

RR (min)

27.1 ± 5.6

24.4 ± 6.3

0.130

SaO2 (%)

85.73 ± 9.6

86.70 ± 8.6

0.630

PaO2 (mmHg)

62.5 ± 11.6

60.4 ± 14.1

0.610

PaCO2 (mmHg)

69.7 ± 10.0

65.4 ± 12.0

0.450

pH

7.28 ± 0.04

7.30 ± 0.03

0.107

FiO2 (%)

38.9 ± 2.9

39.4 ± 3.0

0.570

PS (cmH2O)

18.7 ± 3.35

18.3 ± 2.42

0.585

Ppeak (cmH2O)

18.9 ± 3.7

20.1 ± 2.23

0.181

PEEP (cmH2O)

4.43 ± 0.84

4.16 ± 0.55

0.185

Mean ± standard deviation (mean ± SD). SaO2: Peripheral oxygen saturation, PO2:
partial oxygen pressure, RR: respiratory rate, PCO2: partial carbon dioxide pressure,
FiO2: fraction of inspired O2, PS: pressure support, Ppeak: peak pressure, PEEP: positive
end expiratory pressure, F: full face mask, H: helmet.

There was no significant difference between the groups
in terms of SpO2 values during all study periods (P > 0.05).
SpO2 values were significantly higher at 30, 60, and 120
min in Group F and Group H compared to the initial
values (P < 0.05).
There was no significant difference between the groups
in terms of RR throughout the whole study period (P >
0.05). The diminishing of RR was statistically significant at
60 and 90 min in Group F and 90 and 120 min in Group H
compared to initial values (P < 0.05).
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The PTS at the first hour and second hour of NIMV,
and the NIMV success rate, were not found to be
statistically different between the groups (P > 0.05). The
PS, Ppeak, PEEP, and PaO2/FiO2 values were not found to
be significantly different between the groups (P > 0.05).
The FiO2 values were not statistically different between the
groups (P > 0.05). In Group F, the FiO2 values were not
significantly different when compared to the initial FiO2
value (P > 0.05); it was significantly lower at 60 min in
Group H (P < 0.05).
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There was no difference between groups in terms of
PaCO2 level among the whole study period (P > 0.05).
Decrease in PaCO2 was statistically significant at 60 min
in Group F (P < 0.05). There was no statistically significant
difference in Group H compared to initial PaCO2 values (P
> 0.05) (Figure 1).
The PaO2 values were not significantly different when
comparing the groups (P > 0.05). The PaO2 levels were
increased significantly at 30 and 60 min compared to initial
PaO2 level in both groups (P < 0.05) (Figure 2).
70
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Figure 1. Partial carbon dioxide (PaCO2) level in groups.
#: P < 0.05 in Group F. Values presented as mean ± standard
deviation or patient numbers. H: Helmet, F: full face mask.
80
†

The pH values were not significantly different between
the groups (P > 0.05). The pH values were also found
significantly higher in Group F at 24 and 48 h, and at
discharge from the ICU, compared to the initial value (P <
0.05). In Group H, pH values were found to be significantly
higher at 48 h and at discharge from the ICU compared to
the initial value (P < 0.05) (Figure 3).
When the groups were compared in terms of duration
of ICU and NIMV, no significant difference was found
(P > 0.05) (Table 3). One patient in Group F had cardiac
arrest on the third day of ICU stay. Cardiopulmonary
resuscitation was performed, and the patient died on the
fourth day of the ICU stay. IMV was performed on the
third day of ICU stay in one patient in Group H due to
respiratory failure. Cardiac arrest happened on day 27
and the patient died. Severe respiratory acidosis happened
in another patient in Group H. IMV was performed on
this patient. When the groups were compared in terms of
complications, no significant difference was found (P >
0.05). The mortality rates were similar between the groups
(P > 0.05) (Table 3).
4. Discussion
The NIMV success rate was quite high in this study and
NIMV reduced the complications significantly both in
the full face mask group and in the helmet group during
the study period. The overall outcome was also similar
in the helmet and full face mask groups. The decrease in
PaCO2 was slower in the helmet group, but it was within a
clinically reasonable margin.
Avoiding intubation should significantly reduce the
risk of ventilator-associated lung injury in COPD patients.
NIMV is a functional approach to reduce the IMV
requirement in patients with COPD exacerbation (11). The
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Figure 2. Partial arterial oxygen (PaO2) values.
#: P < 0.05 in Group F, †: P < 0.05 in Group H. Values presented
as mean ± standard deviation. H: Helmet, F: full face mask.
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Figure 3. pH values.
*: P < 0.05: Comparison between groups, #: P < 0.05 in Group
F, †: P < 0.05 in Group H. Values presented as mean ± standard
deviation. H: Helmet, F: full face mask.
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Table 3. Patient outcome.
Group F (n = 23)
Median (min–max)

Group H (n = 25)
Median (min–max)

P-value

Length of ICU stay (days)

6 (4–7)

6 (4–10)

0.84

Duration of NIMV(h)

24 (10–40)

17 (6–31)

0.38

ICU mortality (%)

1/23 (4.3)

1/25 (4)

1.00

Rate of IMV requirement (%)

1/23 (4.3)

2/25(8)

1.00

Rate of complication

14/23 (61)

9/25 (36)

0.15

Values presented as median (25th–75th percentile) or patients number and percentage. H: Helmet, F: full
face mask. ICU: intensive care unit, NIMV: noninvasive mechanical ventilation, IMV: invasive mechanical
ventilation.

performance of NIMV may provide several advantages,
such as relief of dyspnea, improvement of vital signs and
gas exchange, and diminishing of endotracheal intubation
rate (4,12,13). According to these studies, NIMV should be
the first treatment option in COPD cases accompanied by
acute exacerbations. The efficacy of NIMV in an unstable
patient is still controversial. Meduri et al. (5) performed
NIMV in 3 patients who had high PaCO2 levels; the success
rate was high particularly in patients who had pH of 7.25
or higher. High levels of respiratory failure may increase
the IMV requirement. In the present study, we had to
perform IMV in 2 cases in the full face mask group due
to resistant respiratory acidosis within the first 2 h of the
study period. Lower initial pH level of these cases (<7.25)
could explain the failure of NIMV in these patients.
Tolerance of a full face mask is one of the most
important factors for NIMV success. It is quite important
to prevent the need for IMV. Spontaneous ventilation of
the patient and the trigger of the air flow by the ventilator
are related to the patient’s tolerance. Air leakage and an
accurate ventilator setting are other significant factors
affecting the patient’s tolerance (14–16). A comprehensive
explanation of the procedure was provided to the patients,
and close observation was performed throughout our
study. Therefore, we did not observe any significant patient
intolerance in either group. Duration of NIMV is another
important factor for the patient’s tolerance of the NIMV.
The NIMV success rate may be reduced in long-term NIMV
procedures. According to studies the patient tolerance was
reduced by 30% in patients who had a full face mask for
NIMV, and patient tolerance was better with a helmet,
particularly in long-term NIMV procedures (8,17,18). The
helmet has a different design, and the primary aim of the
helmet is to improve the patient’s tolerance (19). Patients
who cannot tolerate the full face mask, who have longterm NIMV requirement, or who have facial deformities
are good candidates for a helmet (17). The helmet also
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permits the patient to talk, read, and drink better than the
facial mask does, improving acceptance and collaboration
between the patient and healthcare professionals (19). In
the present study we did not find any significant difference
according to PTS, but our clinical observations showed that
the tolerance for the helmet was better than for the full face
mask. NIMV-related complications such as discomfort,
skin erythema, claustrophobia, air leaks, eye irritation,
and nasal bridge ulceration might be faced during the
NIMV procedure, and this may require discontinuation of
NIMV. Despite the new advances in face masks, they are
still uncomfortable. This is more problematic, particularly
in dyspneic patients. Facial ulcers may occur in the first
hour of NIMV (6,9). We did not observe claustrophobia
in any patients. Facial laceration and hyperemia were
observed on the noses of 13 patients in the full face mask
group, and axillary laceration and hyperemia were seen
in 10 patients in the helmet group. All lacerations and
hyperemia healed without any treatment. Diminishing of
RR is one of the most important parameters for recovery
from acute respiratory failure. Antanoglia et al. (20) found
that RR diminished in the full face mask and helmet
groups after NIMV. In the present study, our findings are
similar to that study, and diminishing of RR was similar
in all study periods in both groups. Our study has shown
that ABG parameters improved noticeably after the NIMV
procedure, but the diminishing of PaCO2 level was slower
in the helmet group. The large breathing area in the
helmet may cause CO2 rebreathing, and it prevents the fast
diminishing of PaCO2 (21). The volume of the helmet is
approximately 6–8 L. It is negligible when pressure support
is administered at a sufficient level. If the level of pressure
support is kept around 10 cmH2O, the CO2 rebreathing
level is always lower than 1.5%, similar to the face mask
level (20,21). Baglioni et al. (22) performed NIMV with
a helmet in 25 patients who had acute respiratory failure
due to COPD exacerbations. Sixteen patients responded
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to treatment, but NIMV failed in 3 patients due to high
PaCO2 level. On the other hand, we excluded 2 patients
in the full face mask group due to resistant respiratory
acidosis in the first 2 h. Arterial pH appears to be the
paramount marker reﬂecting both the severity of acute
respiratory failure (ARF) and the effect of NIMV in the
acute setting. In accordance with these ﬁndings, in patients
with severe ARF (pH < 7.25), the rate of NIMV failure was
inversely related to the severity of respiratory acidosis.
This indicates that severe acidosis resulting from acute
exacerbation is a relevant predictor for treatment failure of
NIMV (23). In the present study, as well as initial pH levels
above 7.25, the mean pH level was significantly lower in
the full face mask group. Initial PaCO2 levels were also

higher in the full face mask group, but not significantly so.
These results can explain the failure of NIMV in 2 patients
in the full face mask group. In conclusion, both the helmet
and the full face mask are efficient for improving the
patient’s clinical outcome in COPD cases accompanied by
acute exacerbation. However, as reducing of PaCO2 in the
helmet group was slower than in the full face mask group,
it should be negligible in appropriate NIMV settings. A
low pH level might have increased the NIMV failure rate
in COPD cases accompanied by acute exacerbation.
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